From the Guidelines
The estimated half-life of rapamycin in domestic house cats is not directly provided in the given evidence, and therefore, a definitive recommendation cannot be made based on the strongest and most recent evidence. However, considering the general pharmacokinetic properties of rapamycin (sirolimus) in various species, it is known that its half-life can vary significantly. In humans and some animal models, the half-life of sirolimus has been reported to range from approximately 24 to 36 hours, but this information is not directly applicable to domestic house cats without specific feline pharmacokinetic data. Given the lack of direct evidence on the half-life of rapamycin in domestic house cats, veterinarians would need to rely on general principles of pharmacology, the drug's properties in other species, and potentially, pharmacokinetic studies in cats if available, to estimate the half-life and guide dosing decisions. It's also important to consider that individual factors such as a cat's age, liver function, and concurrent medications can influence the actual half-life of drugs like rapamycin in specific animals. Since none of the provided studies 1 directly address the half-life of rapamycin in domestic house cats, a precise estimate based on the most recent and highest quality evidence cannot be provided.
From the Research
Estimated Half-Life of Rapamycin in Domestic House Cats
- The estimated half-life of rapamycin in domestic house cats is not directly stated in the provided studies.
- However, studies 2 and 3 mention that rapamycin has a relatively long half-life in both humans and animals, with 24-hour trough concentrations being within the analytical range of HPLC when immunosuppressive doses are administered.
- These studies do not provide specific information on the half-life of rapamycin in domestic house cats, but they suggest that the half-life of rapamycin is relatively long in animals.
- Studies 4 and 5 focus on the effects of rapamycin on feline hypertrophic cardiomyopathy, but they do not provide information on the half-life of rapamycin in domestic house cats.
- Study 6 discusses the cancer-protecting and promoting effects of immunosuppressants, including rapamycin, but it does not provide information on the half-life of rapamycin in domestic house cats.